The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal
Open accessAbstract
Purpose A multi-institutional phase II trial assessed the utility of dose-painted IMRT (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% as compared to the conventional radiation/5FU/MMC arm from RTOG 9811. Methods and Materials T2-4N0-3M0 anal cancer patients received 5FU and MMC days 1 and 29 of DP-IMRT, prescribed per stage - T2N0: 42Gy elective nodal and 50.4Gy anal tumor planning target volumes (PTVs) in 28 fractions; T3-4N0-3: 45Gy elective nodal, 50.4Gy ≤ 3cm or 54Gy > 3cm metastatic nodal and 54Gy anal tumor PTVs in 30 fractions. The primary endpoint is described above. Planned secondary endpoints assessed all AEs and the investigator’s ability to perform DP-IMRT. Results Of 63 accrued patients, 52 were evaluable. Tumor stage included: 54% II, 25% IIIA, 21% IIIB. In primary endpoint analysis, 77% experienced grade 2+ gastrointestinal/genitourinary acute AEs (9811 77%). There was, however, a significant reduction in acute grade 2+ hematologic, 73% (9811 85%, P=0.032), grade 3+ gastrointestinal, 21% (9811 36%, P=0.0082), and grade 3+ dermatologic AEs 23% (9811 49%, P<0.0001) with DP-IMRT. On initial pre-treatment review, 81% required DP-IMRT re-planning, while final review revealed only three cases with normal tissue major deviations. Conclusions Although the primary endpoint was not met, DP-IMRT was associated with significant sparing of acute grade 2+ hematologic, and grade 3+ dermatologic and gastrointestinal toxicity. While DP-IMRT proved feasible, the high pre-treatment planning revision rate emphasizes the importance of real-time radiation quality assurance for IMRT trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., Peiffert, D., van Glabbeke, M., & Pierart, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2040 · Cited by 1,319
Combined therapy for cancer of the anal canal
Nigro, N. D., Vaitkevicius, V. K., & Considine, B. (1974) · Diseases of the Colon & Rectum · doi:10.1007/bf02586980 · Cited by 1,115
Flam, M. S., John, M., Pajak, T. F., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2527 · Cited by 1,095
Myerson, R. J., Garofalo, M. C., El Naqa, I., Abrams, R. A., Apte, A., Bosch, W. R., Das, P., Gunderson, L. L., Hong, T. S., Kim, J. J. J., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.070 · Cited by 524
Self-citationMell, L. K., Schomas, D. A., Salama, J. K., Devisetty, K., Aydogan, B., Miller, R. C., Jani, A. B., Kindler, H. L., Mundt, A. J., Roeske, J. C., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.08.074 · Cited by 233
Kachnic, L. A., Tsai, H. K., Coen, J. J., Blaszkowsky, L. S., Hartshorn, K., Kwak, E. L., Willins, J. D., Ryan, D. P., & Hong, T. S. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.030 · Cited by 167
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.07.030 · Cited by 481
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu159 · Cited by 355
Electrospun polymer micro/nanofibers as pharmaceutical repositories for healthcare
Feng, X., Li, J., Zhang, X., Liu, T., Ding, J., & Chen, X. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.020 · Cited by 322
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.013 · Cited by 269
Metadata
- Authors
- Kachnic, L. A., Winter, K., Myerson, R. J., Goodyear, M. D., Willins, J., Esthappan, J., Haddock, M. G., Rotman, M., Parikh, P. J., Safran, H., & Willett, C. G.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 86
- Issue
- 1
- Pages
- 27-33
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2076341925
- Cited by
- 621
- References
- 11
- FWCI
- 33.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal. https://app.cochat.ai/papers/10.1016/j.ijrobp.2012.09.023
- The paper
- Kachnic, L. A., Winter, K., Myerson, R. J., Goodyear, M. D., Willins, J., Esthappan, J., Haddock, M. G., Rotman, M., Parikh, P. J., Safran, H., & Willett, C. G. (2013). RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2012.09.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.